1. Home
  2. SCYX vs CENN Comparison

SCYX vs CENN Comparison

Compare SCYX & CENN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SCYX
  • CENN
  • Stock Information
  • Founded
  • SCYX 1999
  • CENN 2013
  • Country
  • SCYX United States
  • CENN United States
  • Employees
  • SCYX N/A
  • CENN N/A
  • Industry
  • SCYX Biotechnology: Pharmaceutical Preparations
  • CENN Auto Manufacturing
  • Sector
  • SCYX Health Care
  • CENN Consumer Discretionary
  • Exchange
  • SCYX Nasdaq
  • CENN Nasdaq
  • Market Cap
  • SCYX 34.9M
  • CENN 28.0M
  • IPO Year
  • SCYX 2014
  • CENN N/A
  • Fundamental
  • Price
  • SCYX $1.10
  • CENN $0.55
  • Analyst Decision
  • SCYX
  • CENN
  • Analyst Count
  • SCYX 0
  • CENN 0
  • Target Price
  • SCYX N/A
  • CENN N/A
  • AVG Volume (30 Days)
  • SCYX 204.1K
  • CENN 209.4K
  • Earning Date
  • SCYX 11-05-2025
  • CENN 11-11-2025
  • Dividend Yield
  • SCYX N/A
  • CENN N/A
  • EPS Growth
  • SCYX N/A
  • CENN N/A
  • EPS
  • SCYX N/A
  • CENN N/A
  • Revenue
  • SCYX $3,257,000.00
  • CENN $30,189,622.00
  • Revenue This Year
  • SCYX $422.61
  • CENN N/A
  • Revenue Next Year
  • SCYX $240.56
  • CENN N/A
  • P/E Ratio
  • SCYX N/A
  • CENN N/A
  • Revenue Growth
  • SCYX N/A
  • CENN 143.95
  • 52 Week Low
  • SCYX $0.66
  • CENN $0.47
  • 52 Week High
  • SCYX $1.66
  • CENN $1.47
  • Technical
  • Relative Strength Index (RSI)
  • SCYX 71.20
  • CENN 50.56
  • Support Level
  • SCYX $0.81
  • CENN $0.52
  • Resistance Level
  • SCYX $1.31
  • CENN $0.56
  • Average True Range (ATR)
  • SCYX 0.07
  • CENN 0.02
  • MACD
  • SCYX 0.03
  • CENN 0.01
  • Stochastic Oscillator
  • SCYX 58.33
  • CENN 63.61

About SCYX SCYNEXIS Inc.

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

About CENN Cenntro Electric Group Limited

Cenntro Inc is a designer, manufacturer, distributor, and service provider of commercial vehicles powered by either electricity or hydrogen energy sources. The company's commercial vehicles are designed to serve a variety of fleet and municipal organizations in support of city services, last-mile delivery, and other commercial applications. It has developed a series of commercial vehicle models, including Metro, Logistar, Logimax, Avantier, Teemak, and Antric One. In addition, the company has introduced an open-platform, programmable all-electric iChassis platform, designed for automated and autonomous driving. Geographically, the company generates maximum revenue from vehicle sales in the United States, and also has a presence in Europe, Asia, and other regions.

Share on Social Networks: